McGraw Hill, Inc.
MH NYSE Miscellaneous Publishing Financials FY2024βFY2026
What McGraw Hill, Inc. does
No business description yet.
- Legal name
- McGraw Hill, Inc.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 10-K Β· Jun 11, 2026
- Accession Β· CIK
- 0001951070-26-000022
0001951070
Revenue and margins
McGraw Hill, Inc. had $2.1B of revenue in fiscal 2026, up 0.1% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was $246M in fiscal 2026, 11.7% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
McGraw Hill, Inc. returned β to shareholders in fiscal 2026. The diluted share count rose 10.2%.
Balance sheet
Cash, debt and the ratios that show how comfortably McGraw Hill, Inc. can carry it.
| Fiscal year end | FY24 | FY25 | FY26 |
|---|---|---|---|
| Cash and short-term investments | $204M | $390M | $254M |
| Debt incl. finance leases | β | $3.2B | $2.6B |
| Net debt / EBITDA | β | 4.1x | 3.6x |
| Debt / equity | β | 11.3x | 3.5x |
| Current ratio | β | 0.8x | 0.8x |
| Quick ratio | β | 0.7x | 0.6x |
| Total assets | β | $5.8B | $5.5B |
| Total liabilities | β | $5.5B | $4.8B |
| Shareholders' equity | $369M | $280M | $726M |
| Net debt (β = net cash) | β | $2.8B | $2.3B |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 3 | β / 5 | 7 / 9 |
| Accruals ratio | β | β12.7% | β5.3% |
| Altman Z'' | β | β0.63 | β0.59 |
3 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY24 | FY25 | FY26 |
|---|---|---|---|
| Income statement | |||
| Revenue | $2.0B | $2.1B | $2.1B |
| Gross profit | $1.5B | $1.7B | $1.7B |
| Research and development | $263M | $284M | $276M |
| Operating income | $155M | $307M | $277M |
| Pretax income | β$168M | $10.6M | $43.8M |
| Income tax | $25.3M | $96.5M | $8.5M |
| Net income | β$193M | β$85.8M | $35.3M |
| Net income to common | β$193M | β$85.8M | $35.3M |
| Diluted EPS | β$1.16 | β$0.52 | $0.19 |
| Diluted shares | 0.17B | 0.17B | 0.18B |
| Cash flow | |||
| Cash from operations | $236M | $646M | $331M |
| Capital expenditure | $82.0M | $71.1M | $84.9M |
| Free cash flow | $154M | $575M | $246M |
| Depreciation and amortization | $366M | $362M | $362M |
| Stock-based compensation | $0.0M | $0.0M | $33.7M |
| Balance sheet | |||
| Cash and short-term investments | $204M | $390M | $254M |
| Total debt | β | $3.2B | $2.6B |
| Finance lease liabilities | β | β | $16.1M |
| Current assets | β | $1.1B | $974M |
| Current liabilities | β | $1.3B | $1.3B |
| Inventory | β | $174M | $195M |
| Goodwill | $2.6B | $2.6B | $2.5B |
| Total assets | β | $5.8B | $5.5B |
| Total liabilities | β | $5.5B | $4.8B |
| Shareholders' equity | $369M | $280M | $726M |
| Margins | |||
| Gross margin | 78.6% | 79.9% | 80.9% |
| Operating margin | 7.9% | 14.6% | 13.2% |
| EBITDA margin | 26.6% | 31.8% | 30.4% |
| Net margin | β9.8% | β4.1% | 1.7% |
| FCF margin | 7.9% | 27.4% | 11.7% |
| Returns | |||
| Return on capital | β | 6.5% | 7.4% |
| Return on capital employed | β | 6.9% | 6.6% |
| Return on equity | β52.3% | β26.5% | 7.0% |
| Return on assets | β | β1.5% | 0.6% |
| Growth | |||
| Revenue growth | β | 7.2% | 0.1% |
| FCF growth | β | 273.0% | β57.2% |
| Share count change | β | 0.0% | 10.2% |
| Financial health | |||
| Net debt / EBITDA | β | 4.1x | 3.6x |
| Debt / equity | β | 11.3x | 3.5x |
| Current ratio | β | 0.8x | 0.8x |
| Quick ratio | β | 0.7x | 0.6x |
| Capital allocation | |||
| Capex / revenue | 4.2% | 3.4% | 4.0% |
| Stock comp / revenue | 0.0% | 0.0% | 1.6% |
| Quality scores | |||
| Piotroski F-score | β | β | 7.0 |
| Altman Z'' | β | β0.6 | β0.6 |
| Accruals ratio | β | β12.7% | β5.3% |
Source: SEC EDGAR XBRL filings (CIK 0001951070). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.